Multi-level analysis of the prevalence of pseudoexfoliative syndrome and pseudoexfoliative glaucoma

Kuleshova, O. N.; Пичикова, Е. А.; Lasareva, A. K.; Aydagulova, S. V.; Dulidova, Veronika V.; Егорова, Э.В.; Черных, В. В.

doi:10.17116/oftalma2017133447-54

Cited by 4 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Similarly, the CGSC, the first nationwide glaucoma registry in China, reported only 41 cases of XFG in a population of 5762 glaucoma cases (0.71%) [ 90 ]. Meanwhile, in the Novosibirsk region of Russia, the XFG appears to account for 70% of open-angle glaucoma cases, much higher than the corresponding rates in European-Russia, suggesting possible environmental influences [ 210 ].…”

Section: Discussionmentioning

confidence: 99%

Molecular Genetics of Glaucoma: Subtype and Ethnicity Considerations

Zukerman

Harris

Vercellin

et al. 2020

Genes

View full text Add to dashboard Cite

Glaucoma, the world’s leading cause of irreversible blindness, is a complex disease, with differential presentation as well as ethnic and geographic disparities. The multifactorial nature of glaucoma complicates the study of genetics and genetic involvement in the disease process. This review synthesizes the current literature on glaucoma and genetics, as stratified by glaucoma subtype and ethnicity. Primary open-angle glaucoma (POAG) is the most common cause of glaucoma worldwide, with the only treatable risk factor (RF) being the reduction of intraocular pressure (IOP). Genes associated with elevated IOP or POAG risk include: ABCA1, AFAP1, ARHGEF12, ATXN2, CAV1, CDKN2B-AS1, FOXC1, GAS7, GMDS, SIX1/SIX6, TMCO1, and TXNRD2. However, there are variations in RF and genetic factors based on ethnic and geographic differences; it is clear that unified molecular pathways accounting for POAG pathogenesis remain uncertain, although inflammation and senescence likely play an important role. There are similar ethnic and geographic complexities in primary angle closure glaucoma (PACG), but several genes have been associated with this disorder, including MMP9, HGF, HSP70, MFRP, and eNOS. In exfoliation glaucoma (XFG), genes implicated include LOXL1, CACNA1A, POMP, TMEM136, AGPAT1, RBMS3, and SEMA6A. Despite tremendous progress, major gaps remain in resolving the genetic architecture for the various glaucoma subtypes across ancestries. Large scale carefully designed studies are required to advance understanding of genetic loci as RF in glaucoma pathophysiology and to improve diagnosis and treatment options.

show abstract

Section: Discussionmentioning

confidence: 99%

Molecular Genetics of Glaucoma: Subtype and Ethnicity Considerations

Zukerman

Harris

Vercellin

et al. 2020

Genes

View full text Add to dashboard Cite

show abstract

Prospective Evaluation of XEN Gel Implant in Eyes With Pseudoexfoliative Glaucoma

Mansouri

Gillmann²,

Rao

et al. 2018

Journal of Glaucoma

View full text Add to dashboard Cite

show abstract

Trabecular microbypass stent implantation in pseudoexfoliative glaucoma: long-term results

Ferguson

Swan

Bleeker

et al. 2020

J Cataract Refract Surg

View full text Add to dashboard Cite

Purpose: To evaluate the long-term safety and efficacy of an iStent trabecular microbypass stent in combination with cataract surgery in pseudoexfoliative glaucoma (PXG). Setting: Private practice, Sioux Falls, South Dakota, USA. Design: Retrospective, consecutive case series. Methods: Eyes with a preoperative diagnosis of PXG implanted with a single iStent trabecular microbypass stent with concomitant cataract surgery were included. Performance outcome measures included intraocular pressure (IOP) and number of glaucoma medications. Safety outcomes included intraoperative or postoperative complications and the need for secondary procedures. Results: The series included 117 eyes. IOP was reduced by 25% to 15.3 ± 3.7 mm Hg at 5 years postoperatively from 20.5 ± 6.6 mm Hg at baseline. The statistically significant (P < .01) 36% reduction in medication use through 36 months was not sustained, and medication use was unchanged from baseline (1.4 ± 1.0) at 5 years postoperatively (1.3 ± 1.1) (P > .05). At 5 years, 52% of eyes had an IOP of 15 mm Hg or lesser, increased from 22% at baseline. There were no severe postoperative complications; 5 eyes (4%) underwent an additional glaucoma procedure. Conclusions: Implantation of a trabecular microbypass stent with concomitant cataract surgery provided a sustained reduction in IOP up to 5 years postoperatively. The long-term safety profile of the device in this population was excellent with a low rate of postoperative IOP spikes and low percentage of eyes undergoing a secondary procedure.

show abstract

Multi-level analysis of the prevalence of pseudoexfoliative syndrome and pseudoexfoliative glaucoma

Abstract: There has been found a high prevalence of PEX and PXFG in the Novosibirsk region. FCBT has demonstrated high hypotensive efficacy at all stages of PXFG and was beneficial even in patients treated with other medications or fixed combinations and in refractory cases.

Cited by 4 publications

References 14 publications

Molecular Genetics of Glaucoma: Subtype and Ethnicity Considerations

Molecular Genetics of Glaucoma: Subtype and Ethnicity Considerations

Prospective Evaluation of XEN Gel Implant in Eyes With Pseudoexfoliative Glaucoma

Trabecular microbypass stent implantation in pseudoexfoliative glaucoma: long-term results

Contact Info

Product

Resources

About